Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (Nasdaq: CRSP) said members of its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 8:15 a.m. PT in San Francisco.

A live webcast will be available on the company’s Events & Presentations page at https://crisprtx.gcs-web.com/events, and a replay will be archived on the company website for 14 days following the presentation.

CRISPR Therapeutics (Nasdaq: CRSP) provided a broad update on zugocaptagene geleucel (zugo-cel), an allogeneic anti-CD19 CAR T, across autoimmune diseases and B-cell malignancies on Dec 22, 2025. Key clinical readouts include deep B-cell depletion and drug-free DORIS remission through Month 6 in an SLE patient at the 100 million cell dose, and in R/R large B-cell lymphoma an ORR 90% and CRR 70% at the 600 million cell RP2D. Safety findings: Grade 3 CRS and ICANS each at 17% and serious infections 8% at the RP2D. A Phase 1 basket study in ITP and wAIHA has started and a collaboration with Lilly will evaluate zugo-cel plus pirtobrutinib. Additional data expected H2 2026.

CRISPR Therapeutics (Nasdaq: CRSP) reported Q3 2025 results and a business update on Nov 10, 2025. Cash, cash equivalents, and marketable securities were $1,944.1M as of Sept 30, 2025. Net loss for Q3 was $106.4M. R&D expense decreased to $58.9M and collaboration expense increased to $57.1M for the quarter. Commercial momentum for CASGEVY continues: ~165 patients completed first cell collection and 39 patients received infusions to date; Vertex expects >$100M in CASGEVY revenue for 2025. Key clinical updates: positive Phase 1 CTX310 data published in NEJM, CTX460 preclinical correction >90%, pediatric exa-cel Phase 3 enrollment completed with data due Dec 6, 2025.

CRISPR Therapeutics (Nasdaq: CRSP) reported positive Phase 1 data for CTX310 on Nov 8, 2025, presented at AHA Scientific Sessions and published in NEJM. A single-course IV infusion produced dose-dependent, durable editing of ANGPTL3 with a mean reduction of -73% (max -89%). At the highest dose, mean triglycerides (TG) fell -55% (max -84%; mean -60% in patients with baseline TG >150 mg/dL) and mean LDL fell -49% (max -87%) by Day 60. CTX310 was generally well tolerated in 15 participants with no treatment-related serious adverse events and no ≥Grade 3 transaminase changes. CRISPR is advancing CTX310 into Phase 1b, prioritizing severe hypertriglyceridemia and mixed dyslipidemia.

CRISPR Therapeutics (NASDAQ: CRSP) reported preclinical CTX460 data using its SyNTase™ editing platform for Alpha-1 Antitrypsin Deficiency (AATD). Key results shown at ESGCT 2025 include >90% mRNA correction, a 5-fold increase in total serum AAT, and an >99% M-AAT:Z-AAT ratio in disease models after a single dose. Near-saturating hepatocyte editing occurred at doses as low as 0.1 mg/kg, with >90% mRNA correction at 0.5 mg/kg and durability of effect up to 7–9 weeks in rodent models.

CTX460 is formulated in a proprietary LNP and is expected to enter clinical testing in mid-2026, positioning the program as a potential best-in-class, mutation‑targeting approach for AATD.

Monash University, Australia's largest research institution, has announced the establishment of the Monash Boston Hub in Cambridge to strengthen its biotech partnerships in North America and Europe. The Hub will facilitate licensing, drug discovery, and clinical trial collaborations.

The university has completed over 160 license deals and created 30+ spinouts in the past five years, collectively raising nearly $1 billion. The new Hub, staffed by 5-7 professionals led by Nathan Elia, will be located at the Cambridge Innovation Center.

Notable partnerships include Moderna's mRNA manufacturing facility on Monash's campus and collaborations with CRISPR Therapeutics (NASDAQ: CRSP). The university's Monash Institute of Pharmaceutical Sciences (MIPS) has helped progress over 40 novel drug candidates into clinical development.

CRISPR Therapeutics (Nasdaq: CRSP) announced the upcoming presentation of its novel SyNTase gene editing technology at the ESGCT 2025 Annual Congress. The presentation will showcase preclinical data for treating Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder.

The SyNTase platform combines compact Cas9 proteins with engineered polymerases, achieving up to 95% editing efficiency in cell models with minimal off-target effects. In preclinical studies, a single intravenous dose (≤0.5 mg/kg) demonstrated high efficiency in humanized mouse models, while achieving >70% mRNA correction and >3-fold total serum AAT upregulation in humanized rat models of AATD.

The presentation is scheduled for October 10, 2025, at 11:00 a.m. CEST during the Gene Editing III session.

CRISPR Therapeutics (NASDAQ: CRSP) and Sirius Therapeutics have announced the dosing of the first patient in a Phase 2 clinical trial of SRSD107, their co-developed Factor XI (FXI) siRNA therapy for preventing venous thromboembolism in total knee arthroplasty patients.

SRSD107 demonstrated promising results in Phase 1 trials, showing over 93% reduction in FXI levels and a twofold increase in aPTT relative to baseline. The treatment's effects were sustained for up to six months post-dosing, suggesting potential for semi-annual administration.

The therapy aims to address limitations of current anticoagulants by reducing pathological thrombosis while minimizing bleeding risk. The addressable market includes patients with atrial fibrillation, VTE, cancer-associated thrombosis, and various cardiovascular conditions where bleeding risk currently limits treatment options.

CRISPR Therapeutics (Nasdaq: CRSP) announced it will present late-breaking data at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, from November 7-10, 2025.

The company will showcase two key presentations: A late-breaking oral presentation on Phase 1 clinical data for CTX310™, their CRISPR/Cas9 gene editing therapy targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and a poster presentation on CTX340™, their preclinical program targeting angiotensinogen for refractory hypertension treatment.

The presentations are scheduled for November 8, 2025, with the CTX310 data presented at 8:30 a.m. CST and the CTX340 poster at 2:30 p.m. CST. Presentation materials will be available on the company's website after the sessions.